Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEN High-Risk Neuroblastoma Study 2
MOH_2022-12-08_012228Phase 3Not yet recruiting
- Sponsor
- SIOPEN
- Start
- Dec 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, vincristine, etoposide, dacarbazine, thiotepa and 2 more in neuroblastoma (6 arms), sponsored by SIOPEN. Primary endpoints: Tumor regression during induction, Outcome of single versus tandem high-dose chemotherapy/transplant and 1 more. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
cisplatinvincristineetoposidedacarbazinethiotepa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on MOH_2022-12-08_012228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-08_012228.